Glucose-lowering treatment of type 2 diabetes: Part II - glucose-lowering drugs after metformin: A choice based largely on adverse effects

Prescrire International

Volumn 24, Issue 160, 2015, Pages 130-135

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

BULLOUS PEMPHIGOID; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONSTIPATION; DEPRESSION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FRACTURE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INFORMED CONSENT; KIDNEY FAILURE; LIVER INJURY; MYALGIA; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; VOMITING; WEIGHT GAIN; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84928948528     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Prescrire Editorial Staff "Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects" Prescrire Int 2014; 23 (154): 269-272.
2. Bennet WL et al. "Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update" Comparative Effectiveness Review, No. 27; Agency for Healthcare Research and Quality, Rockville (MD) March 2011: 658 pages.
3. Bolen S et al. "Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes" Comparative Effectiveness Review, No. 8; Agency for Healthcare Research and Quality, Rockville (MD) July 2007: 219 pages.
4. McIntosh B et al. "Second line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis" Open Medicine 2011; 5 (1): 35-48.
5. Liu SC et al. "Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis" Diab Obes Metab 2012; 14 (9): 810-820.
6. Prescrire Rédaction "4-1. Patients diabétiques" Rev Prescrire 2014; 34 (374 suppl. interactions médicamenteuses).
7. UK Prospective Diabetes Study (UKPDS) Group "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" Lancet 1998; 352: 837-853.
8. Monami M et al. "Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials" Diabetes Obes Metab 2013; 15 (10): 938-953.
9. UK Prospective Diabetes Study (UKPDS) Group "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" Lancet 1998; 352: 854-865.
10. Home PD et al. "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial" Lancet 2009; 373: 2125-2135.
11. Prescrire Rédaction "insulines-Actrapid-HM°, Monotard-HM°, Umuline ordinaire°, Umuline Protamine Isophane (NPH)°" Rev Prescrire 1984; 4 (37): 4-5.
12. Prescrire Editorial Staff "Insulin in type 2 diabetes: a useful alternative... despite limited assessment based on surrogate endpoints" Prescrire Int 2005; 14 (79) : 187-193.
13. Prescrire Rédaction "insuline glargine-Lantus°. Premier analogue de l'insuline à action prolongée" Rev Prescrire 2005; 25 (261): 325-332.
14. Prescrire Editorial Staff "Insulin detemir: a second long-acting insulin analogue: many uncertainties, few advantages" Prescrire Int 2006; 15 (85): 163-167.
15. Prescrire Editorial Staff "Insulin degludec. Uncertainty over cardiovascular harms" Prescrire Int 2014; 23 (150): 149.
16. Colmers IN et al. "Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies" Diabetes Metab 2012; 38 (6): 485-506.
17. Karlstad Ø et al. "Use of insulin and insulin analogs and risk of cancer. Systematic review and meta-analysis of observational studies" Curr Drug Saf 2013; 8 (5): 333-348.
18. Hemmingsen B et al. "Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses" BMJ 2012; 344: e1771: 19 pages.
19. Prescrire Editorial Staff "Acarbose tablets" Prescrire Int 1996; 5 (26): 164-166.
20. Prescrire Rédaction "miglitol-Diastabol°. Pas mieux que l'acarbose" Rev Prescrire 1999; 19 (199): 646-649.
21. Prescrire Editorial Staff "Intestinal alpha-glucosidase inhibitors: abdominal gas cysts" Prescrire Int 2012; 21 (130): 212-213.
22. Prescrire Rédaction "Hépatites dues à l'acarbose" Rev Prescrire 1998; 18 (190): 841.
23. Prescrire Editorial Staff "Repaglinide and diabetes: no better than glucose-lowering sulphonamides" Prescrire Int 2001; 10 (51): 9-11.
24. Prescrire Rédaction "Insuffisance cardiaque et diabète de type 2" Rev Prescrire 2008; 28 (294): 284.
25. Prescrire Rédaction "Rosiglitazone: vers une suspension d'AMM européenne, enfin !" Rev Prescrire 2010: 30 (325): 817.
26. Prescrire Rédaction "Pioglitazone: cancers de la vessie (suite)" Rev Prescrire 2011; 31 (335): 668.
27. Prescrire Editorial Staff "Pioglitazone: European approval maintained despite the acknowledged risks: chaotic regulation" Prescrire Int 2012; 21 (129): 181.
28. Prescrire Editorial Staff "Sitagliptin. Type 2 diabetes: limited efficacy, too many unknown risks" Prescrire Int 2008; 17 (93): 12-15.
29. Prescrire Editorial Staff "Vildagliptin and vildagliptin/metformin. Same limited efficacy as sitagliptin in type 2 diabetes" Prescrire Int 2008; 17 (97): 188.
30. Prescrire Editorial Staff "Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions" Prescrire Int 2011; 20 (113): 33-37.
31. Prescrire Editorial Staff "Linagliptin. Avoid gliptins!" Prescrire Int 2013; 22 (135): 36-37.
32. Egan AG et al. "Pancreatic safety of incretin-based drugs - FDA and EMA assessment" N Engl J Med 2014; 370 (9): 794-797 + 370 (23): 2253.
33. Prescrire Rédaction "Gliptines: pemphigoïdes bulleuses" Rev Prescrire 2014; 34 (373): 829.
34. Prescrire Editorial Staff "Saxagliptin, alone or in combination. No fewer complications: more cases of heart failure?" Prescrire Int 2014; 23 (152): 207.
35. Elashoff M et al. "Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies" Gastroenterology 2011; 141 (1): 150-156.
36. Prescrire Rédaction "Exénatide commercialisé: ne pas banaliser" Rev Prescrire 2008; 28 (295): 340.
37. Prescrire Editorial Staff "Liraglutide. Type 2 diabetes: more prudent to continue using exenatide" Prescrire Int 2010; 19 (107): 109-112.
38. Prescrire Editorial Staff "Exenatide. Type 2 diabetes: for some overweight patients" Prescrire Int 2007; 16 (92): 228-482319.
39. Prescrire Editorial Staff "Dapagliflozin. A hypoglycaemic drug causing disproportionate harm, especially to kidneys" Prescrire Int 2014; 23 (147): 61-64.
40. Prescrire Rédaction "canagliflozine-Invokana°. Me-too de la trop dangereuse dapagliflozine" Rev Prescrire 2014; 35 (372): 733-736.
41. Prescrire Rédaction "Prévenir et traiter la rétinopathie diabétique" Rev Prescrire 1995; 15 (148): 114-123 + (151): 400.
42. Hemmingsen B et al. "Targeting intensive glycaemic control versus conventional glycaemic control for type 2 diabetes mellitus" (Cochrane review) (last update: 2012). In: "The Cochrane Library" John Wiley and sons, Chichester 2013; issue 11: 380 pages.
43. Prescrire Rédaction "Chirurgie de l'obésité chez les diabétiques" Rev Prescrire 2009; 29 (308) : 451-452.
44. "Replaglinide". In: "Martindale The Complete Drug Reference" The Pharmaceutical Press, London. www.medicinescomplete.com accessed 19 October 2014 : 9 pages.